Table 3.

Multivariable analyses to evaluate association of baseline htTKV with CKD progression

Renal insufficiency endpoint		Unadjusted model			Adjusted model*
Measured GFR (iothalamate)	N	OR	95% CI	P value	OR	95% CI	P value
30–59 (CKD Stage 3)	184	1.53	(1.31, 1.77)	<0.001	1.38	(1.19, 1.60)	<0.001
15–29 (CKD Stage 4)	179	1.52	(1.33, 1.75)	<0.001	1.42	(1.23, 1.64)	<0.001
<15 (CKD Stage 5) or ESRD	177	1.44	(1.26, 1.64)	<0.001	1.35	(1.18, 1.55)	<0.001
GFR decreased ≥ 30%	182	1.66	(1.36, 2.02)	<0.001	1.61	(1.31, 1.98)	<0.001
GFR decreased ≥ 57%	180	1.49	(1.30, 1.70)	<0.001	1.43	(1.24 1.65)	<0.001
eGFR (MDRD formula)
30–59 (CKD Stage 3)	183	1.91	(1.54, 2.37)	<0.001	1.69	(1.35, 2.11)	<0.001
15–29 (CKD Stage 4)	181	1.51	(1.32, 1.73)	<0.001	1.43	(1.25, 1.65)	<0.001
<15 (CKD Stage 5) or ESRD	177	1.44	(1.26, 1.64)	<0.001	1.35	(1.18, 1.55)	<0.001
GFR decreased ≥ 30%	181	1.55	(1.30, 1.86)	<0.001	1.56	(1.28, 1.91)	<0.001
GFR decreased ≥ 57%	180	1.48	(1.29, 1.68)	<0.001	1.40	(1.22, 1.60)	<0.001
eGFR (CKD-EPI formula)
30–59 (CKD Stage 3)	183	1.93	(1.56, 2.40)	<0.001	1.71	(1.38, 2.14)	<0.001
15–29 (CKD Stage 4)	180	1.55	(1.35, 1.79)	<0.001	1.47	(1.27, 1.70)	<0.001
<15 (CKD Stage 5) or ESRD	177	1.44	(1.26, 1.64)	<0.001	1.35	(1.18, 1.55)	<0.001
GFR decreased ≥ 30%	181	1.54	(1.29, 1.84)	<0.001	1.45	(1.21, 1.74)	<0.001
GFR decreased ≥ 57%	180	1.46	(1.28, 1.66)	<0.001	1.39	(1.22, 1.59)	<0.001

GFR values in mL/min/1.73 m²

OR, odds ratio of reaching CKD stage per 100 mL/m increment in baseline htTKV

^*Adjusted for age, sex, race, BMI and baseline GFR